Alopecia

Read the latest articles about Alopecia, Hair Loss and other related problems and their treatment.

Finasteride for Male Pattern Hair Loss

Finasteride 1 mg (Propecia®, Merck) was approved by the US FDA December, 1997 for the treatment of male pattern hair loss (androgenetic alopecia, AGA) in men only. Safety and efficacy were demonstrated in men between 18 and 41 years of age with mild to moderate hair loss of the vertex and anterior mid-scalp area.

5% Minoxidil: Treatment for Female Pattern Hair Loss

Minoxidil is a Health Canada and US FDA-approved medication for hair loss in men and women. This article review recent Phase III clinical trials on Minoxidil efficacy for the treatment of female patter hair loss.

The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions

Oral JAK inhibitors are now the first-line treatment for advanced alopecia areata, surpassing topical JAK inhibitors. Baricitinib's FDA approval in 2022 was a significant milestone. More JAK inhibitors are being studied, and additional medications may gain approval soon. JAK inhibitors show promise for alopecia areata with a generally good safety profile, but long-term data is lacking.

DSM-5 Update in Psychodermatology

This update summarizes current concepts, relevance, and therapeutics in psychodermatology, including aspects pertinent to depression, anxiety, obsessive-compulsive, impulse-control, and delusional disorders as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)

Promising Therapies for Treating and/or Preventing Androgenic Alopecia

Androgenetic alopecia (AGA) may affect up to 70% of men and 40% of women at some point in their lifetime. Here we briefly review current therapeutic options and treatments under active investigation.

Chemotherapy-Induced Hair Loss

Chemotherapy-induced hair loss occurs with an estimated incidence of 65%. This article discusses hair loss, topical minoxidil, scalp cooling and chemotherapy induced hair loss.

Frontal Fibrosing Alopecia

Frontal fibrosing alopecia has become one of the most frequently seen causes of scarring alopecia at many specialist hair clinics. It has distinctive features and associations which distinguish it from LPP. Discussion includes familial or genetic factors, etiology, and trials.

Utilization of Topical Ruxolitinib in Dermatology: A Review

Topical ruxolitinib shows promise in various dermatological conditions, including atopic dermatitis, vitiligo, psoriasis, and lichen planus, with a favorable safety profile compared to oral JAK inhibitors. However, its effectiveness in alopecia areata remains inconclusive.

Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors

Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, represent a new class of medication that have broad potential to treat dermatologic disease.

Female Hair Loss

Androgenetic alopecia is a stressful experience for both sexes, but possibly more distressing for women. An overview of the condition, treatments, and considerations surrounding alopecia.

What’s New In Hair Transplants?

As hair transplant surgery has evolved, combinations of micrografting and minigrafting have enabled physicians to produce ever more natural combinations of both. A wide range of men and women can now receive significant aesthetic benefits from hair transplants.

Androgenetic Alopecia: A Review of Topical Agents for Hair Growth Promotion (Pharmacist)

Hair loss is a common dermatological problem that affects a large segment of the population both physically and psychologically. Currently, only one topical agent is approved for treatment of hair loss in men, although other treatments are being clinically investigated.

Updates on the Management of Autoimmune Blistering Diseases

Autoimmune blistering diseases are rare, but potentially debilitating characterized by varying degrees of mucosal and cutaneous bullae formation. This article discusses individually tailored treatment, diagnosis, severity, comorbidities, and tolerance for systemic therapy.

DPCP for the Treatment of Alopecia Areata

Topical immunotherapy with diphencyprone (DPCP) for the treatment of severe alopecia areata has been used since 1983 and is felt to be the treatment of choice by many dermatologists. Although there have been no major side effects reported since its initial use, there remain some unknowns regarding its safety.

Popular in Alopecia

Advertisement